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Abstract
Background: Atrial fibrillation (AF) is a common clinical problem and potent risk factor for stroke. However, 
real-world effectiveness and outcomes for AF patients are not well described.
Objective: To compare the economic and clinical impact of stroke and warfarin use on patients with non-
valvular atrial fibrillation (NVAF).
Methods: This was a retrospective analysis of medical and pharmacy claims of NVAF patients from a large 
commercial health insurance database (01/01/2005-12/31/2007). Patients were grouped according to stroke 
or warfarin prescription status. For all groups, demographic, clinical, and pharmaceutical characteristics were 
analyzed descriptively. Risk-adjusted overall and cardiovascular-related hospital readmission rates in 30 days, 
length of stay (LOS), clinical outcomes, and health care costs were assessed using propensity score matching.  
Costs were adjusted to 2007 U.S. dollars using the medical component of  the U.S. Consumer Price Index. 
Results: Out of 18,575 NVAF patients, 3.1% (n=575) experienced a stroke event. Stroke patients were older 
on average (78.94 vs. 77.28 years, p-value<0.0001) with significantly higher risk-adjusted inpatient mortality 
(7.14% vs. 2.09%, p-value<0.0001), emergency room visits (79.97% vs. 46.34%, p-value<0.0001), and average 
LOS measures (overall: 10.20 vs. 6.83 days, p<0.0001; cardiovascular-related: 8.35 vs. 5.90 days, p-value<0.0001). 
Despite the similarity in Charlson Comorbidity Index scores compared to non-stroke controls, stroke patients 
significantly higher clinical outcome rates during follow-up for acute coronary syndrome (ACS), ischemic 
attack, major and minor bleeding patients (p-values<0.0100), and the total cost incurred was nearly three times 
greater ($33,506 vs. $13,921, p-values<0.0001). NVAF patients were commonly prescribed warfarin (65.60%) 
and appeared to have a lower prevalence of clinical outcomes, while not incurring significantly higher follow-
up costs compared to those not prescribed warfarin ($12,739, standard deviation [SD]=$19,842 vs. $15,358; 
SD=$45,446; p-value>0.0500). However, a significantly greater proportion of patients with major and minor 
bleeding were prescribed a combination of  warfarin and antiplatelets than those without these events.
Conclusions: A stroke after an NVAF diagnosis has a major clinical impact, which translates into a significant 
economic burden for patients. Warfarin prescriptions did not significantly impact total health care costs, though 
caution is advised to minimize hemorrhagic events.  
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INTRODUCTION
Atrial fibrillation (AF) is the most common significant cardiac arrhythmia, affecting an estimated 2.3 million 
adults in the United States. Its prevalence increases with age, approximately doubling each decade in individuals 
over age 50 years. In those over age 65 years, AF prevalence is estimated to be 6%1 and roughly 10% in persons 
age 80 years or older.2,3
AF patients have six times the risk of ischemic stroke, due to cardiogenic embolism, than age-matched controls, 
resulting in approximately 80,000 strokes per year in North America.4 The risk of stroke in AF patients increases 
with advancing age and the presence of concomitant risk factors including left ventricular dysfunction, history 
of hypertension, stroke or transient ischemic attack (TIA), and diabetes mellitus (DM).5  Medical therapy 
has been shown to ameliorate several complications associated with AF, particularly with regard to reducing 
stroke risk.6 Among appropriate diagnosed AF patients, anticoagulation can reduce the risk of a first stroke by 
approximately 68%,7 and it is the recommended therapy in published guidelines.8   Therefore, an expert panel 
has recommended that all AF patients over age 75 should be considered for chronic anticoagulation therapy, 
unless a contraindication exists.
Elderly patients with an ischemic stroke associated with AF are at especially high risk for a recurrent stroke with 
an annual rate of more than 10% per year.9 Secondary preventative therapy with warfarin is highly effective in 
reducing this risk. The recurrence rate can be reduced by two thirds with warfarin therapy. Warfarin use was 
also confirmed to decrease mortality.10  
AF is a common clinical problem and potent risk factor for stroke, yet there is a lack of studies focusing on the 
real-world effectiveness and safety of outcomes for AF patients.
METHODS 
Study Sample 
This study used data from a large U.S. commercial database from 2003 to 2008. Table 1 represents patient 
attrition. The prevalence of  stroke was analyzed in selected patients aged 65 years or older with claims for at 
least two primary diagnoses for AF (determined using the International Classification of  Diseases 9th Revision 
Clinical Modification [ICD-9-CM] codes in Appendix Table A1) occurring within 30 days of  one another. 
Additional criteria for study selection included continuous health plan enrollment for at least 180 days prior to 
the initial AF diagnosis date (designated as the index date), and the earlier date of  at least 180 days following 
the first AF diagnosis date or until death.  
Patients were excluded if  they had at least one medical claim for any the following:  transient AF caused by 
a reversible disorder, known presence of  atrial myxoma, left ventricular thrombus, active endocarditis, any 
diagnosis of  arterial or venous thromboembolism (VTE), use of  selected antiplatelet or anticoagulant agents 
(low-molecular-weight [LMWH] and unfractionated heparin [UFH], fondaparinux, anisindione, abciximab, 
cilostazol, anagrelide, pentoxifylline, enoxaparin, dalteparin, or clopidogrel), before the first AF diagnosis. 
Patients must have had continuous enrollment for at least 180 days before and after the first prescription date. 
From this final sample (n=19,268), cohorts were assigned; patients were assigned to appropriate cohorts.
Table 1. Attrition Table
Condition Sample Size
Initial Sample Size 269,339
2 or more AF diagnoses occurring within 30 days of  one another 145,938
Age 65 years and older (according to first AF 
diagnosis date) 140,913
Continuous enrollment for at least 180 days pre- 
first AF diagnosis date and at least 180 days 
following first AF diagnosis date or until death, whichever comes first 90,319
AF, atrial myxoma, left ventricular thrombus, 
active endocarditis, any diagnosis of  arterial or VTE, planned cardioversion or 
trauma diagnose before first AF diagnosis (index) date were excluded. 23,373
Patients prescribed selected antiplatelet or anticoagulant agents (dalteparin, 
enoxaparin, tinzaparin, heparin sodium in dextrose, heparin sodium, 
heparin sodium injection, heparin sodium/sodium chloride, fondaparinux, 
anisindione, abciximab, cilostazol, anagrelide, pentoxifylline) before first 
diagnosis date were excluded. 19,702
Continuous enrollment for at least 180 days prior to first prescription date and 
at least 180 days following first prescription date. 19,268
Diagnosed with NVAF 18,575
AF=atrial fibrillation; VTE=venous thromboembolism; NVAF=non-valvular atrial fibrillation
Non-valvular AF (NVAF) patients did not have pre-index claims indicating the presence of  transient, 
perioperative AF, valvular heart disease or concomitant hyperthyroidism or prescriptions for methimazole or 
propylthiouracil.
Cohort Assignment
NVAF patients were stratified into the following cohorts based on follow-up criteria:
Warfarin or Non-warfarin Cohorts: Patients included in the Warfarin Cohort had at least one prescription for 
warfarin or dicumarol after the index date, more than one outpatient international normalized ratio (INR) 
(current procedural terminology [CPT] code: 99211), or a diagnosis or warfarin therapy in the 3 months 
after initial identified AF diagnosis during the study period, or any combination of  these factors. The date of  
whichever came first was designated as the drug index date; and
Stroke or Non-stroke Cohorts: Stroke Cohort patients had at least one claim for an ischemic or hemorrhagic stroke 
in the follow-up period (ICD-9-CM codes: 430.xx, 431.xx, 432.xx, 433.xx, 434.xx, 436.0).
COVARIATES AND OUTCOME VARIABLES
Patient Characteristics
Many aspects of  health care utilization and cost, including treatment selection, therapy patterns, and health 
outcomes, may be associated with factors not directly measured in administrative claims data. Vast literature 
exist demonstrating differences in a variety of health-related outcomes for patients of differing educational
attainment, income, net worth, race and ethnicity and family structure. Therefore, various patient and clinical 
factors to estimate risk-adjusted comparisons were captured.
Age was defined as of the index date. In addition, patient age was used to assign them to the following 
age groups: 65-74, 75-84, 85-94, 95+. Median and maximum values were also provided. Gender and U.S. 
region variables (Northeast, North Central, South, and West) were included as well. The most commonly used 
comorbidity index in health outcomes studies is the Charlson Comorbidity Index (CCI), which assigns a weight 
ranging from 1 to 6 according to disease severity for 19 conditions.11 The index has since adopted several 
weights, some of  which allow outpatient diagnoses to contribute to the score.12,13
Comorbid Conditions
The Appendix Table lists disease codes for comorbid conditions and clinical outcomes measured for the 
baseline period (≥180 days pre-index date). Patients were flagged for the following conditions: end stage renal 
disease (ESRD), congestive heart failure (CHF), peripheral arterial disease (PAD), acute coronary syndrome 
(ACS), hyperthyroidism, obesity, DM, hypertension, ischemic stroke, hemorrhagic stroke, non-central nervous 
system (CNS) systemic embolism, TIA, catheter ablation, and dyspepsia. Studied medications included warfarin, 
injectable anticoagulants (enoxaparin, dalteparin, and fondaparinux), antiplatelets (plavix), and combinations 
thereof.
Outcome Variables
A flag was created for each of the following variables occurring after the index date (Table 2): in-hospital 
mortality, average number of health care visits per patient per year (pppy), readmission rates 30 days after 
discharge, length of stay (LOS) (all-cause and cardiovascular-related), ACS, ischemic stroke, hemorrhagic stroke, 
TIA, major bleeding, non-major clinically relevant bleeding, non-CNS systemic embolism, surgical ablation, 
cardioversion, intra-cardiac device, myocardial infarction (MI), osteopathic fracture, intracranial hemorrhage 
(ICH), and gastrointestinal (GI) bleeding.
Average total annual health care costs per patient were captured as well. Since the analysis is from the payer’s 
perspective, reimbursement amounts rather than charges were applied. Expenditures were expressed in 2007 
U.S. dollars and were adjusted using the medical component of  the U.S. Consumer Price Index. 
STATISTICAL ANALYSIS
Baseline and outcome measures were descriptively analyzed using numbers/percentages for dichotomous 
and means/standard deviation (SD) for continuous variables.  Bivariate comparisons were implemented using 
t-tests or chi-square tests when appropriate with standardized differences included. Non-parametric tests (e.g. 
the Mann Whitney U-test) were applied if  there was a deviation from asymptotical assumptions.
Multivariate analysis was performed using 1:1 propensity score matching (PSM).  Propensity scores were 
estimated via unconditional logistic regression analysis to yield risk-adjusted estimates (or remove overt bias). 
Patients were matched if their propensity scores were within ±0.01 units of one another. Covariates in the 
logistic regression model included age, gender, baseline CCI score, baseline comorbid conditions, baseline 
health care utilization, and baseline health care costs. To estimate total cost, a generalized linear model (GLM) 
with gamma distribution and log link function with cost as the dependent variable and demographic/clinical 
factors used in PSM as independent variables.
Table 2. Descriptive Statistics for NVAF Patients who did or did not Experience a Stroke
NVAF Patients (N=18,575)
No Stroke (N=18,000) Stroke (N=575)
Mean/N SD/% Mean/N SD/% P-value Std Diff
Pre-period (180 days before AF diagnosis date)
Age (mean) 77.28 7.12 78.94 6.77 0 23.99
Median 77 79
Maximum 103 96
65-74 6788 37.71% 152 26.43% 0 24.33
75-84 8161 45.34% 295 51.30% 0.0047 11.95
85-94 2911 16.17% 124 21.57% 0.0006 13.81
95+ 140 0.78% 4 0.70% 0.8251 0.96
Gender (Male) 8852 49.18% 275 47.83% 0.5233 2.7
Region
Northeast 1892 10.51% 50 8.70% 0.1613 6.16
North Central 6372 35.40% 228 39.65% 0.036 8.79
South 4999 27.77% 165 28.70% 0.6266 2.05
West 4720 26.22% 131 22.78% 0.0645 8
Comorbid Conditions
Elixhauser Index Score (≥2%) 0.06 0.24 0.05 0.21 0.1697 5.52
CCI Score 0.19 0.7 0.22 0.81 0.3459 4.25
ESRD 45 0.25% 4 0.70% 0.0403 6.5
CHF 697 3.87% 13 2.26% 0.0473 9.35
PAD 27 0.15% 3 0.52% 0.0289 6.42
ACS 442 2.46% 11 1.91% 0.4064 3.71
Obesity 10 0.06% 1 0.17% 0.2508 3.49
Diabetes 299 1.66% 9 1.57% 0.8593 0.76
Hypertension 636 3.53% 17 2.96% 0.4597 3.25
Ischemic Stroke 335 1.86% 30 5.22% 0 18.23
Hemorrhagic Stroke 19 0.11% 6 1.04% 0 12.42
TIA 120 0.67% 4 0.70% 0.933 0.35
Catheter Ablation 6 0.03% 0 0.00% 0.6615 2.58
Dyspepsia 6 0.03% 0 0.00% 0.6615 2.58
Pharmacotherapy Pattern (AF diagnosis date – June 2007)
Warfarin 11818 65.66% 368 64.00% 0.4107 3.47
Injectable Anticoagulant 144 0.80% 2 0.35% 0.2268 5.99
Antiplatelet 545 3.03% 44 7.65% 0 20.67
Other Drug 4764 26.47% 134 23.30% 0.0902 7.32
Other Drug (Antiarrhythmic) 560 3.11% 19 3.30% 0.793 1.1
Other Drug(Rate Control Drugs) 2008 11.16% 61 10.61% 0.6816 1.76
No Medication 729 4.05% 27 4.70% 0.4405 3.16
Warfarin and Anticoagulant 793 4.41% 37 6.43% 0.0204 8.97
Warfarin and Antiarrhythmic 3358 18.66% 117 20.35% 0.3057 4.27
Warfarin and Antiplatelets 516 2.87% 29 5.04% 0.0023 11.18
Warfarin and Rate Control 9691 53.84% 300 52.17% 0.4305 3.33
Warfarin and Antidepressants 399 2.22% 20 3.48% 0.0449 7.59
NVAF=non-valvular atrial fibrillation; SD=standard deviation; AF=atrial fibrillation; CCI=Charlson comorbidity index  ESRD=end-stage renal 
disease; CHF=congestive heart failure; PAD=peripheral arterial disease; ACS=acute coronary syndrome; TIA=transient ischemic attack
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Multivariate analysis was performed using 1:1 propensity score matching (PSM).  Propensity scores were 
estimated via unconditional logistic regression analysis to yield risk-adjusted estimates (or remove overt bias). 
Patients were matched if their propensity scores were within ±0.01 units of one another. Covariates in the 
logistic regression model included age, gender, baseline CCI score, baseline comorbid conditions, baseline 
health care utilization, and baseline health care costs. To estimate total cost, a generalized linear model (GLM) 
with gamma distribution and log link function with cost as the dependent variable and demographic/clinical 
factors used in PSM as independent variables.
RESULTS
Stroke vs. Non-stroke Cohorts
Of all NVAF patients, 3.10% experienced a stroke during the study period (n=575, Table 2). These stroke-
experienced patients were older on average (78.94 vs. 77.28 years, p-value<0.0001) and had higher frequencies 
of ESRD (0.70% vs. 0.25%, p-value=0.040), PAD (0.52% vs. 0.15%, p-value=0.029), but lower frequency of 
CHF (2.26% vs. 3.87%, p-value=0.047) relative to those who did not suffer a stroke prior to NVAF diagnosis. 
Stroke-experienced patients were more frequently prescribed antiplatelets (7.65% vs. 3.03%, p-value<0.0001) 
or warfarin combinations with either anticoagulants (6.43% vs. 4.41%, p-value=0.020) or antiplatelets (5.04% 
vs. 2.87%, p-value=0.002) compared to non-stroke patients. 
After PSM (Table 3), stroke patients had significantly higher risk-adjusted rates of inpatient mortality (7.14% vs. 
2.09%, p-value<0.0001), emergency room (ER) visits (79.97% vs. 46.34%, p-value<0.0001), and average LOS 
measures (overall: 10.20 vs. 6.83 days, p-value<0.0001; cardiovascular-related: 8.35 vs. 5.90 days, p-value<0.0001). 
Significantly higher average clinical outcome rates per 100 pppy also occurred for the following conditions: 
ACS (14.98 vs. 5.57, p-value=0.0003), TIA (25.44 vs. 1.39, p-value<0.0001), major bleeding (29.62 vs. 1.39, 
p-value<0.0001) and minor bleeding (18.82 vs. 4.18, p-value<0.0001). Many post-index period comorbid 
conditions (ESRD, CHF, PAD, DM, hypertension) were more common in stroke patients as well. Consistent 
with the high adverse event rates and complex comorbidity profile, patients who experienced a stroke had 
health care costs nearly three times greater than patients who did not experience a stroke ($33,506 vs. $13,921, 
p-value<0.0001).
Table 3. Risk-adjusted Outcomes for NVAF Patients who did or did not Experience Stroke
After Match N=574 for Each Group
No Stroke Stroke
Mean/N SD/% Mean/N SD/% P-value Std Diff
Mortality-Inpatient 12 2.09% 41 7.14% <0.0001 24.23
# Patients with Inpatient Visit 255 44.43% 574 100.00%  <0.0001 158.04
# Patients with ER Visit 266 46.34% 459 79.97% <0.0001 74.30
# Patients with Outpatient Visit 541 94.25% 532 92.68% 0.2786 6.34
# Patients with INR Visit 143 24.91% 111 19.34% 0.0223 13.45
Readmission Rate (30 days) 0 0.00% 10 1.74%  <0.0001 18.81
LOS 7.11 10.7 10.05 12.25 <0.0001 25.60
Cardiovascular-related
Readmission Rate (30 days) 0 0.00% 10 1.74%  <0.0001 18.81
LOS 5.9 6.98 8.35 9.53 <0.0001 29.34
Clinical Outcomes (100 person-years)
ACS 16 5.57 43 14.98 0.0003 21.41
TIA 4 1.39 73 25.44 <0.0001 49.46
Major Bleeding 4 1.39 85 29.62 <0.0001 54.66
Non-major Clinical Relevant Bleeding 12 4.18 54 18.82 <0.0001 31.80
Non-CNS Systemic Embolism 4 1.39 8 2.79 0.2482 6.85
Stroke or Non-CNS Systemic Embolism 4 1.39 574 200.00 <0.0001 1686.72
Catheter Ablation 2 0.70 4 1.39 0.4142 4.83
PCI 2 0.70 2 0.70 1.0000 0.00
CABG Surgery 1 0.35 13 4.53 0.0013 19.12
MI 9 3.14 32 11.15 0.0002 21.70
Osteoporotic Fracture 4 1.39 16 5.57 0.0073 16.02
Dyspepsia 0 0.00 3 1.05 <0.0001 10.24
ICH 0 0.00 77 26.83 <0.0001 55.62
GI Bleeding 3 1.05 7 2.44 0.1573 7.50
Health Care Cost
Total Health Care Costs $16,375 $65,996 $33,430 $55,050 <0.0001 28.06
SD=standard deviation; INR=international normalized ratio; LOS=length of  stay; ACS=acute coronary syndrome; TIA=transient 
ischemic attack; CNS=central nervous system; PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft; 
MI=myocardial infarction; ICH=intracranial hemorrhage; GI=gastrointestinal
NVAF Patients with/without Warfarin Prescription
Among 18,575 patients with NVAF, 12,816 were included in the Warfarin Cohort and 6,389 were in the Non-
warfarin Cohort (Table 4).  The Warfarin Cohort was relatively young (76.64 vs. 78.65 years, p-value<0.0001) 
and healthy, with a lower CCI index score (0.15 vs. 0.27, p-value<0.0001) and lower proportion of  patients 
with nearly all comorbid conditions except hyperthyroidism, obesity, non-CNS systemic embolism, catheter 
ablation, or dyspepsia (p-values>0.0500). The resulting unadjusted total health care costs were lower for patients 
prescribed warfarin ($13,906, SD=$27,285 vs. $15,712, SD=$44,832; p-value=0.0033). Since these measures 
are confounded with baseline characteristics, PSM was applied.
Table 4. Descriptive Statistics for NVAF Patients Prescribed Warfarin or Not
NVAF Patients (N=18,575)
Non-warfarin Cohort Warfarin Cohort
(N=6,389) (N=12,186)
Mean/N SD/% Mean/N SD/% P-value Std Diff
Pre-period 
(180 days pre-AF diagnosis date)
Age (mean) 78.65 7.77 76.64 6.64 0 27.8
Median 79 76
Maximum 102 103
65-74 2,103 32.92% 4,837 39.69% 0 14.13
75-84 2,699 42.24% 5,757 47.24% 0 10.06
85-94 1,480 23.16% 1,555 12.76% 0 27.35
95+ 107 1.67% 37 0.30% 0 13.89
Gender (Male) 2,864 44.83% 6,263 51.40% 0 13.17
Region
Northeast 654 10.24% 1,288 10.57% 0.4808 1.09
North Central 2,217 34.70% 4,383 35.97% 0.0865 2.65
South 1,808 28.30% 3,356 27.54% 0.2728 1.69
West 1,701 26.62% 3,150 25.85% 0.2536 1.76
Comorbid Conditions
CCI Score 0.27 0.86 0.15 0.61 0 16.66
ESRD 27 0.42% 22 0.18% 0.0022 4.42
CHF 300 4.70% 410 3.36% 0 6.77
PAD 18 0.28% 12 0.10% 0.0031 4.21
ACS 179 2.80% 274 2.25% 0.0202 3.53
Obesity 3 0.05% 8 0.07% 0.6189 0.79
Diabetes 131 2.05% 177 1.45% 0.0024 4.56
MI 93 1.46% 120 0.98% 0.0042 4.29
Hypertension 296 4.63% 357 2.93% 0 8.94
Ischemic Stroke 159 2.49% 206 1.69% 0.0002 5.58
Hemorrhagic Stroke 20 0.31% 5 0.04% 0 6.47
TIA 56 0.88% 68 0.56% 0.0113 3.77
Catheter Ablation 0 0.00% 6 0.05% 0.0761 3.14
Dyspepsia 1 0.02% 5 0.04% 0.3605 1.51
Pharmacotherapy  Pattern 
(AF diagnosis date - June 2007)
Warfarin 0 0.00% 12,186 100.00% 0 0
Injectable Anticoagulant 146 2.29% 0 0.00% 0 21.63
Antiplatelet 589 9.22% 0 0.00% 0 45.06
Other Drug 4,898 76.66% 0 0.00% 0 256.3
Other Drug (Rate Control Drugs) 2,069 32.38% 0 0.00% 0 97.86
No Medication 756 11.83% 0 0.00% 0 51.81
Warfarin and Anticoagulant 0 0.00% 830 6.81% 0 38.23
Warfarin and Antiarrhythmic 0 0.00% 3,475 28.52% 0 89.32
Warfarin and Antiplatelets 0 0.00% 545 4.47% 0 30.6
Warfarin and Rate Control 0 0.00% 9,991 81.99% 0 301.71
NVAF=non-valvular atrial fibrillation; SD=standard deviation; AF=atrial fibrillation; CCI=Charlson comorbidity index; ERD=end-stage renal disease; CHF=congestive 
heart failure; PAD=peripheral arterial disease; ACS=acute coronary syndrome; MI=myocardial infarction; TIA=transient ischemic attack
After matching, the adjusted outcomes of  5,966 warfarin and non-warfarin control patients were compared. 
Warfarin patient in-hospital mortality (0.75% vs. 2.26%, p-value<0.0001) and ER visit rates (48.79% vs. 
53.30%, p-value<0.0001) and average cardiovascular-related hospital LOS (5.81 vs. 5.84 days, p-value<0.0001) 
were lower than those of  the matched controls (Table 5). While the rates of  clinical outcomes per 100 pppy 
were generally similar, warfarin patients had lower rates of  ACS (3.52 vs. 5.16, p-value=0.0022) and MI (2.04 
vs. 3.75, p-value<0.0001) and a higher rate of  TIA (2.15 vs. 1.41, p-value=0.033) compared to non-warfarin 
patients. The resulting health care costs for warfarin and non-warfarin patients was similar after risk adjustment 
($12,739, SD=$19,842 vs. $15,358, SD=$45,446; p-value>0.0500). In the post-index period, warfarin patients 
had higher follow-up rates of  CHF (21.25 vs. 17.40, p-value=0.0003) but lower rates of  ESRD (0.64 vs. 1.64, 
p-value=0.0003).
Table 5. Risk-adjusted Outcomes for NVAF Patients Prescribed Warfarin or Not
After Match N=5,966 for each Cohort
Non Warfarin Cohort Warfarin Cohort
Mean/N SD/% Mean/N SD/% P-value SD
Mortality-Inpatient 135 2.26% 45 0.75% <0.0001 12.4
# Patients with Inpatient Visit 2615 43.83% 2706 45.36% 0.0913 3.07
# Patients with ER Visit 3180 53.30% 2911 48.79% <0.0001 9.03
# Patients with Outpatient Visit 5428 90.98% 5842 97.92% <0.0001 30.67
# Patients with INR Visit 340 5.70% 2197 36.83% <0.0001 82.25
Readmission Rate (30 days) 22 0.37% 18 0.30% 0.5271 1.16
LOS 7.76 13.88 6.54 7.92 0.066 10.75
Cardiovascular-related
Readmission Rate (30 days) 12 0.20% 16 0.27% 0.4497 1.39
LOS 5.84 8.51 5.81 6.1 <0.0001 0.47
Clinical Outcomes (100 person-years)
ACS 154 5.16 105 3.52 0.0022 5.64
Ischemic Stroke 167 5.6 178 5.97 0.5502 1.1
Hemorrhage Stroke 33 1.11 23 0.77 0.1814 2.45
TIA 42 1.41 64 2.15 0.0326 3.93
Major Bleeding 75 2.51 88 2.95 0.3026 1.88
Non-major Clinical Relevant Bleeding 148 4.96 137 4.59 0.5102 1.21
Non-CNS Systemic Embolism 37 1.24 48 1.61 0.2328 2.19
Stroke or Non-CNS Systemic Embolism 225 7.54 234 7.84 0.6703 0.78
Catheter Ablation 25 0.84 38 1.27 0.1015 3.01
PCI 45 1.51 29 0.97 0.0593 3.42
CABG Surgery 14 0.47 9 0.3 0.2971 1.91
MI 112 3.75 61 2.04 <0.0001 7.16
Osteoporotic Fracture 65 2.18 45 1.51 0.0565 3.51
Dyspepsia 5 0.17 2 0.07 0.2568 2.08
ICH 37 1.24 26 0.87 0.1658 2.54
GI Bleeding 32 1.07 49 1.64 0.0589 3.47
Health Care Costs
Total Health Care Costs $15,359 $45,446 $12,739 $19,842 0.3704 7.47
SD=standard deviation; INR=international normalized ratio; LOS=length of  stay; ACS=acute coronary syndrome; TIA=transient ischemic 
attack; CNS=central nervous system; PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft; MI=myocardial infarction; 
ICH=intracranial hemorrhage; GI=gastrointestinal
NVAF Patient Pharmacotherapy Patterns with Adverse Outcomes
NVAF patients with major bleeding (n=266) were prescribed warfarin plus antiplatelet combinations (6.02% 
vs. 2.89%, p-value=0.0027) significantly more often than those without major bleeding (n=18,309) (Table 6). 
Similarly, when NVAF patients with non-major bleeding (n=454) were compared to controls lacking non-major 
bleeding (n=18,121), more non-major bleeding patients were prescribed warfarin+antiplatelets after an AF 
diagnosis (4.63% vs. 2.89%, p-value=0.0306).  
NVAF patients diagnosed with GI bleeding (n=145) were prescribed warfarin significantly more often than the 
18,430 patients without GI bleeding (74.48% vs. 65.53%, p-value=0.0239).  However, no significant difference 
was found when comparing warfarin+antiplatelet prescriptions (5.52% vs. 2.91%, p-value=0.0643). NVAF 
patients who experienced ICH (n=84) were prescribed warfarin alone less often than the 18,491 patients 
without ICH (53.57% vs. 65.66%, p-value=0.0200), and despite a higher absolute frequency of  ICH patients 
with warfarin+antiplatelet prescriptions (5.95% vs. 2.92%, p-value=0.1004), the difference was not statistically 
significant.  
Table 6. Pharmacotherapy Patterns for Patients with Bleeding/Hemmorhagic Outcomes after AF Diagnosis
Non-major Bleeding (%)
P-value












63.66 65.65 0.3764 74.48 65.53 0.0239 53.57 65.66 0.02
4.63 2.89 0.0306 5.52 2.91 0.0643 5.95 2.92 0.1004
GI=gastrointestinal; ICH=intracranial hemmorhage
DISCUSSION
Stroke in NVAF patients is a clinically relevant event with increased spending implications in Medicare 
Supplemental patients. Warfarin was commonly prescribed to NVAF patients without a significant increase 
in total health care expenses. Consideration of the dose intensity of warfarin may help avoid hemorrhagic 
complications.
An established adverse event associated with warfarin use is hemorrhage, particularly when in combination with 
antiplatelets.14,15 Observational data from this study generally support this claim; a significantly greater proportion 
of patients with major and minor bleeding were prescribed a combination of warfarin and antiplatelets than 
those without these events.  Absolute frequencies of warfarin and antiplatelet use were higher in GI bleeding 
and ICH patients, though their small sample sizes may have contributed to the lack of statistical significance, 
compared to controls without these conditions. These considerations should be kept in mind when creating an 
optimal treatment plan for NVAF patients. 
A major strength of this study involves the use of a large database of nationwide, physician-designated hospital 
diagnoses with real-world spending figures from a recent time period.  While claims data are extremely valuable 
for the efficient and effective examination of health care outcomes, treatment patterns, and costs, claims data 
are collected for the purpose of  payment and not research. Therefore, there are certain limitations associated 
with the use of claims data. The presence of a claim for a filled prescription does not indicate that the 
medication was consumed or that it was taken as prescribed. Additionally, the presence of a diagnosis code on 
a medical claim is not positive presence of  disease, as the diagnosis code may be incorrectly coded or included 
as rule-out criteria rather than actual disease. Finally, certain information is not readily available in claims
data that could have an effect on study outcomes, such as clinical and disease-specific parameters. 
It should be noted that neither regression adjustment addresses problems due to imbalances in unmeasured 
factors. It is quite possible that outcomes for patients with the same observable characteristics can vary because 
of unobservable factors such as physician or practice-prescribing patterns. There are several methods that 
exist to control for unmeasured factors such as the instrumental variable approach, bounding approach and 
a difference-in-difference estimator. However, these estimators are also confounded by their own limitations.
CONCLUSIONS
A stroke after an NVAF diagnosis has a major clinical and economic impact on patients. Stroke-experienced 
patients had higher average clinical outcome rates than non-stroke controls as well as more frequent health 
care resource use (ER visits and longer average hospital LOS) and higher inpatient mortality. These factors 
contributed to annual total health care costs for stroke-experienced patients nearly three times greater than for 
those who did not experience a stroke. 
Stroke incidence is nearly 5-fold higher in AF patients, so diagnosed patients must be monitored carefully 
and provided with appropriate pharmacotherapy to avert stroke events.16,17 NVAF patients were commonly 
prescribed warfarin and appear to have a lower prevalence of  clinical outcome conditions, while not incurring 
significantly higher follow-up costs compared to those not prescribed warfarin. 
It should be noted that warfarin patients were also younger than controls on average and had a less complex 
comorbidity profile than patients without a warfarin prescription. Additional research would be necessary to 
confirm and explain the real-world outcomes seen in this population in a causative manner.
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